Gargoyle Investment Advisor Has Upped By $1.19 Million Its Owens Corning New (OC) Position; Last Week SCYNEXIS, Inc. (SCYX) Analysts

December 7, 2017 - By Marguerite Chambers

Gargoyle Investment Advisor Llc increased Owens Corning New (OC) stake by 53.95% reported in 2017Q2 SEC filing. Gargoyle Investment Advisor Llc acquired 18,061 shares as Owens Corning New (OC)’s stock rose 7.09%. The Gargoyle Investment Advisor Llc holds 51,540 shares with $3.45 million value, up from 33,479 last quarter. Owens Corning New now has $9.69 billion valuation. The stock increased 0.47% or $0.41 during the last trading session, reaching $87.06. About 167,753 shares traded. Owens Corning (NYSE:OC) has risen 23.07% since December 7, 2016 and is uptrending. It has outperformed by 6.37% the S&P500.

Among 7 analysts covering Scynexis Inc (NASDAQ:SCYX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Scynexis Inc had 13 analyst reports since August 20, 2015 according to SRatingsIntel. WBB Securities upgraded the stock to “Buy” rating in Tuesday, August 9 report. H.C. Wainwright maintained the shares of SCYX in report on Wednesday, August 16 with “Buy” rating. WBB Securities initiated the stock with “Strong Buy” rating in Tuesday, December 29 report. As per Thursday, October 20, the company rating was initiated by H.C. Wainwright. On Monday, November 16 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock of SCYNEXIS, Inc. (NASDAQ:SCYX) earned “Buy” rating by Needham on Thursday, August 20. The firm has “Strong Buy” rating given on Friday, October 7 by WBB Securities. The company was initiated on Monday, March 28 by Brean Capital. The stock of SCYNEXIS, Inc. (NASDAQ:SCYX) has “Buy” rating given on Wednesday, August 17 by Guggenheim. Brean Capital initiated it with “Buy” rating and $16 target in Monday, October 3 report. See SCYNEXIS, Inc. (NASDAQ:SCYX) latest ratings:

24/10/2017 Broker: Guggenheim Rating: Buy New Target: $6 Initiates Coverage On
16/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $14.0 Maintain
09/08/2017 Broker: Needham Rating: Hold Maintain
07/08/2017 Broker: Roth Capital Rating: Buy New Target: $8.5000 Maintain

Investors sentiment decreased to 1 in 2017 Q2. Its down 0.80, from 1.8 in 2017Q1. It is negative, as 8 investors sold SCYNEXIS, Inc. shares while 7 reduced holdings. 7 funds opened positions while 8 raised stakes. 9.22 million shares or 20.12% less from 11.54 million shares in 2017Q1 were reported. Federated Invsts Pa, a Pennsylvania-based fund reported 4.21 million shares. Rock Springs Cap Ltd Partnership reported 0.07% in SCYNEXIS, Inc. (NASDAQ:SCYX). National Asset Management stated it has 307,630 shares or 0.1% of all its holdings. Fmr Ltd Liability has invested 0% in SCYNEXIS, Inc. (NASDAQ:SCYX). Morgan Stanley holds 0% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX) for 15 shares. Royal Comml Bank Of Canada reported 0% stake. Granite Point Capital Lp holds 0.06% or 141,750 shares. Gsa Prns Limited Liability Partnership, a United Kingdom-based fund reported 176,700 shares. Two Sigma Limited Liability owns 0% invested in SCYNEXIS, Inc. (NASDAQ:SCYX) for 10,304 shares. Bridgeway Capital Mngmt Inc has 50,000 shares. Iguana Limited Liability Corporation stated it has 0.23% in SCYNEXIS, Inc. (NASDAQ:SCYX). Geode Cap Mgmt Ltd Limited Liability Company reported 128,724 shares. Us National Bank & Trust De holds 0% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX) for 500 shares. Opus Point Prtnrs Management Lc reported 0.11% stake. Moreover, California Pub Employees Retirement has 0% invested in SCYNEXIS, Inc. (NASDAQ:SCYX).

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. The company has market cap of $60.55 million. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. It currently has negative earnings. The firm also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis.

The stock increased 0.47% or $0.01 during the last trading session, reaching $2.12. About 22,231 shares traded. SCYNEXIS, Inc. (NASDAQ:SCYX) has declined 46.67% since December 7, 2016 and is downtrending. It has underperformed by 63.37% the S&P500.

Since June 14, 2017, it had 0 buys, and 2 selling transactions for $1.54 million activity. Genis Arnaud had sold 21,544 shares worth $1.41M on Wednesday, June 14. 2,000 shares were sold by McMonagle James J, worth $129,200 on Thursday, June 15.

Investors sentiment decreased to 0.94 in 2017 Q2. Its down 0.17, from 1.11 in 2017Q1. It worsened, as 27 investors sold OC shares while 126 reduced holdings. 42 funds opened positions while 102 raised stakes. 102.55 million shares or 3.39% less from 106.14 million shares in 2017Q1 were reported. Parametric Assoc Ltd Liability Company has invested 0.03% in Owens Corning (NYSE:OC). Jacobs Levy Equity Mngmt Inc holds 87,070 shares. Vident Advisory Limited Co holds 0.23% or 40,869 shares in its portfolio. Moreover, Wellington Management Llp has 0% invested in Owens Corning (NYSE:OC) for 101,968 shares. Par Capital owns 2.44 million shares. Barrow Hanley Mewhinney & Strauss holds 7.18M shares or 0.73% of its portfolio. Moreover, Holderness Communication has 0.16% invested in Owens Corning (NYSE:OC) for 4,474 shares. Bkd Wealth Advsrs Limited Liability Corporation reported 5,297 shares. 200 were reported by Pathstone Family Office Llc. Northpointe Limited Liability Co invested in 0.28% or 40,348 shares. Utah Retirement has 20,312 shares. Wells Fargo Mn owns 462,347 shares. Glenmede Trust Na holds 60,760 shares or 0.02% of its portfolio. Nationwide Fund Advsr reported 0.05% of its portfolio in Owens Corning (NYSE:OC). Centurylink Investment Mgmt has invested 0.57% of its portfolio in Owens Corning (NYSE:OC).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :